IMNR - Immune Response Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMNR - Immune Response

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mark B. Martell, CCM who wrote (178)	11/24/1997 10:00:00 AM
From: Robert DeHaven	Read Replies (1) of 1510

Hey Marcus: The stock will move after 12/1..IMHO and as stated before to a new high in or around $17. The driving force now is the expected corporate collaberation that IMNR is perceived to need to go to the next level....As you are probably aware the cost to develop and bring to market a drug such as Remune is approximately $200 million. Now, with its approval seemingly close at hand the deals to market it and put on the market are happening behind the scene. The stock price will not wait for the final FDA word. It'll move up in advance of that news. It is generally expected to be approved. Technically, I look for continued weakness through 12/1 and then $17 by month end 12/97. Good luck, Bob

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next